Talzenna 0.25 mg hard capsules, Talzenna 0.1 mg hard capsules, Xtandi - 40 mg film-coated tablets clinical trials

“A randomized phase II trial to evaluate the antitumor activity of Enzalutamide and Talazoparib (PF-06944076) for the treatment of metastatic hormone-naïve prostate cancer”

This study is testing new treatments for prostate cancer that has spread and hasn't been treated with hormone therapy before. It compares two drugs, Talzenna and Xtandi, to see how well they shrink the cancer and stop it from growing, focusing on a blood test called PSA.